Health Care [ 6/12 ] | Biotechnology [ 45/74 ]
NASDAQ | Common Stock
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma.
The company was incorporated in 2024 and is based in La Jolla, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 5, 24 | 125.48 Increased by +11.72 K% | -1.51 Increased by +8.41 K% |
| May 9, 24 | -1.44 Decreased by -28.57% | -1.04 Decreased by -38.46% |
| Feb 28, 24 | -1.73 Decreased by -82.11% | -1.04 Decreased by -66.35% |
| Nov 9, 23 | -1.10 Decreased by -22.22% | -1.01 Decreased by -8.91% |
| Aug 7, 23 | -1.08 Decreased by -11.34% | -1.03 Decreased by -4.85% |
| May 8, 23 | -1.12 Decreased by -40.00% | -0.84 Decreased by -33.33% |
| Mar 6, 23 | -0.95 Decreased by -72.73% | -0.79 Decreased by -20.25% |
| Nov 7, 22 | -0.90 Decreased by -66.67% | -0.94 Increased by +4.26% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 100.00 K Increased by +233.33% | 1.86 B Increased by +4.05 K% | Increased by +1.86 M% Increased by +1.28 K% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -78.71 M Decreased by -61.65% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.63 M Increased by +496.35% | -93.60 M Decreased by -128.78% | Decreased by -5.73 K% Increased by +61.64% |
| Sep 30, 23 | 119.00 K Decreased by -57.19% | -51.79 M Decreased by -27.41% | Decreased by -43.52 K% Decreased by -197.65% |
| Jun 30, 23 | 30.00 K Decreased by -95.78% | -47.05 M Decreased by -24.70% | Decreased by -156.84 K% Decreased by -2.86 K% |
| Mar 31, 23 | 17.00 K Decreased by -98.14% | -48.69 M Decreased by -45.39% | Decreased by -286.42 K% Decreased by -7.73 K% |
| Dec 31, 22 | 274.00 K Decreased by -90.34% | -40.91 M Decreased by -93.10% | Decreased by -14.93 K% Decreased by -1.90 K% |
| Sep 30, 22 | 278.00 K Decreased by -88.92% | -40.65 M Decreased by -97.51% | Decreased by -14.62 K% Decreased by -1.68 K% |